CORT · Corcept Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $164.90M | - | $207.64M | $194.43M | $157.21M | - | $182.55M | $163.80M | $146.81M | - |
| Cost of Revenue | $2.88M | - | $4.60M | $3.43M | $2.40M | - | $2.87M | $2.52M | $2.54M | - |
| Gross Profit | $162.02M | - | $203.04M | $191.00M | $154.81M | - | $179.68M | $161.27M | $144.27M | - |
| R&D | $66.27M | - | $68.85M | $60.47M | $60.73M | - | $59.34M | $58.74M | $58.51M | - |
| SG&A | $145.36M | - | $123.98M | $103.85M | $90.66M | - | $73.75M | $66.94M | $56.27M | - |
| Total Operating Expenses | $214.50M | - | $197.42M | $167.75M | $153.80M | - | $135.95M | $128.20M | $117.31M | - |
| D&A | $598.0K | - | - | - | $285.0K | - | - | - | $68.0K | - |
| Operating Income | ($49.60M) | - | $10.22M | $26.68M | $3.42M | - | $46.60M | $35.59M | $29.50M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($12.95M) | - | ($4.42M) | ($3.46M) | ($10.93M) | - | $5.73M | $6.11M | $7.23M | - |
| Net Income | ($31.76M) | - | $19.67M | $35.15M | $20.55M | - | $47.21M | $35.49M | $27.76M | - |
| EPS - Basic | ($0.30) | - | $0.19 | $0.33 | $0.19 | - | $0.45 | $0.34 | $0.27 | - |
| EPS - Diluted | ($0.30) | - | $0.16 | $0.29 | $0.17 | - | $0.41 | $0.32 | $0.25 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $108.74M | $120.50M | $125.14M | $102.75M | $89.82M | $127.67M | $137.29M | $128.59M | $149.75M | $135.55M |
| Accounts Receivable | $39.07M | $59.79M | $69.63M | $64.57M | $61.82M | $53.98M | $59.72M | $53.84M | $61.52M | $41.12M |
| Inventory | $12.89M | $12.87M | $12.35M | $12.28M | $14.37M | $12.41M | $8.05M | $8.35M | $7.19M | $7.73M |
| Accounts Payable | $33.31M | $40.44M | $34.45M | $23.52M | $27.95M | $15.38M | $18.58M | $19.48M | $12.56M | $17.40M |
| Current Assets | $426.03M | $485.46M | $541.13M | $443.11M | $438.50M | $471.60M | $466.98M | $560.85M | $503.37M | $458.64M |
| Total Assets | $814.88M | $836.65M | $823.61M | $801.72M | $846.46M | $840.55M | $784.26M | $714.55M | $655.93M | $621.52M |
| Current Liabilities | $149.19M | $166.09M | $172.26M | $144.66M | $143.07M | $140.77M | $126.22M | $100.75M | $97.20M | $104.50M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $176.89M | $188.85M | $191.71M | $165.93M | $163.17M | $160.96M | $145.42M | $118.31M | $108.07M | $114.81M |
| Stockholders' Equity | $637.99M | $647.80M | $631.90M | $635.79M | $683.28M | $679.59M | $638.84M | $596.24M | $547.86M | $506.70M |
| Retained Earnings | $611.63M | $643.39M | $619.10M | $599.43M | $564.28M | $543.74M | $512.99M | $465.78M | $430.29M | $402.53M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.77M) | - | - | - | $5.13M | - | - | - | $23.76M | - |
| Investing Cash Flow | $4.54M | - | - | - | ($3.17M) | - | - | - | ($9.01M) | - |
| Financing Cash Flow | $760.0K | - | - | - | ($39.80M) | - | - | - | ($543.0K) | - |
| CapEx | $201.0K | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($16.97M) | - | - | - | $5.13M | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 98.3% | - | 97.8% | 98.2% | 98.5% | - | 98.4% | 98.5% | 98.3% | - |
| Operating margin | -30.1% | - | 4.9% | 13.7% | 2.2% | - | 25.5% | 21.7% | 20.1% | - |
| EBITDA margin | -29.7% | - | - | - | 2.4% | - | - | - | 20.1% | - |
| Net margin | -19.3% | - | 9.5% | 18.1% | 13.1% | - | 25.9% | 21.7% | 18.9% | - |
| Free cash flow margin | -10.3% | - | - | - | 3.3% | - | - | - | - | - |
| FCF / Net income | 0.53 | - | - | - | 0.25 | - | - | - | - | - |
| R&D / Revenue | 40.2% | - | 33.2% | 31.1% | 38.6% | - | 32.5% | 35.9% | 39.9% | - |
| SG&A / Revenue | 88.1% | - | 59.7% | 53.4% | 57.7% | - | 40.4% | 40.9% | 38.3% | - |
| Effective tax rate | - | - | -29.0% | -10.9% | -113.6% | - | 10.8% | 14.7% | 20.7% | - |
| Return on assets | -3.9% | - | 2.4% | 4.4% | 2.4% | - | 6.0% | 5.0% | 4.2% | - |
| Return on equity | -5.0% | - | 3.1% | 5.5% | 3.0% | - | 7.4% | 6.0% | 5.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.86 | 2.92 | 3.14 | 3.06 | 3.07 | 3.35 | 3.70 | 5.57 | 5.18 | 4.39 |
| Quick ratio | 2.77 | 2.85 | 3.07 | 2.98 | 2.96 | 3.26 | 3.64 | 5.48 | 5.10 | 4.31 |
| Cash ratio | 0.73 | 0.73 | 0.73 | 0.71 | 0.63 | 0.91 | 1.09 | 1.28 | 1.54 | 1.30 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.28 | 1.29 | 1.30 | 1.26 | 1.24 | 1.24 | 1.23 | 1.20 | 1.20 | 1.23 |
| Liabilities / Assets | 0.22 | 0.23 | 0.23 | 0.21 | 0.19 | 0.19 | 0.19 | 0.17 | 0.16 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.25 | 0.24 | 0.19 | - | 0.23 | 0.23 | 0.22 | - |
| Inventory turnover | 0.22 | - | 0.37 | 0.28 | 0.17 | - | 0.36 | 0.30 | 0.35 | - |
| Days sales outstanding | 86d | - | 122d | 121d | 144d | - | 119d | 120d | 153d | - |
| Days inventory outstanding | 1632d | - | 981d | 1305d | 2182d | - | 1025d | 1208d | 1035d | - |
| Days payable outstanding | 4217d | - | 2736d | 2501d | 4245d | - | 2366d | 2818d | 1808d | - |
| Cash conversion cycle | -2498d | - | -1632d | -1075d | -1919d | - | -1222d | -1490d | -620d | - |
| Valuation | ||||||||||
| P / E | - | - | 519.4x | 253.1x | 671.9x | - | 112.9x | 101.5x | 100.8x | - |
| P / B | 6.6x | - | 15.7x | 13.9x | 20.0x | - | 8.2x | 6.1x | 5.1x | - |
| P / S | 25.5x | - | 47.8x | 45.5x | 87.1x | - | 28.8x | 22.1x | 18.9x | - |
| EV / EBITDA | - | - | - | - | 3673.6x | - | - | - | 88.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 4.9% | - | 13.7% | 18.7% | 7.1% | - | 47.7% | 39.1% | 39.0% | - |
| Revenue CAGR (3y) | 16.0% | - | 26.8% | 23.4% | 18.8% | - | 23.8% | 21.4% | 22.7% | - |
| Revenue CAGR (5y) | 15.7% | - | 19.2% | 17.0% | 11.0% | - | 17.5% | 17.8% | 17.8% | - |
| Gross profit growth (YoY) | 4.7% | - | 13.0% | 18.4% | 7.3% | - | 47.3% | 38.9% | 38.4% | - |
| Operating income growth (YoY) | - | - | -78.1% | -25.1% | -88.4% | - | 49.5% | 20.3% | 98.6% | - |
| Net income growth (YoY) | - | - | -58.3% | -1.0% | -26.0% | - | 50.5% | 28.9% | 74.8% | - |
| EPS growth (YoY) | - | - | -61.0% | -9.4% | -32.0% | - | 46.4% | 28.0% | 78.6% | - |
| EPS CAGR (3y) | - | - | -18.9% | 6.5% | -5.3% | - | 19.5% | 15.1% | 11.6% | - |
| EPS CAGR (5y) | - | - | -1.2% | 4.7% | -7.4% | - | 13.3% | 13.5% | 10.8% | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | -31.2% | - | - | - | - | - |
| Book value growth (YoY) | -6.6% | -4.7% | -1.1% | 6.6% | 24.7% | 34.1% | 38.4% | 41.4% | 3.5% | 1.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CORCEPT THERAPEUTICS INC against the 5 most active filers in the same SIC group.